文献速递男科与性医学

基于国际勃起功能指数评分对睾酮治疗男性性功能结果的Meta分析

Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores.
PubMed 文献 · Eur Urol · 2017-04-20

该Meta分析纳入14项安慰剂对照随机临床试验共2298名男性,平均随访40.1周,平均年龄60.2±6.5岁,以IIEF勃起功能域为主要结局。结果显示睾酮治疗较安慰剂显著改善勃起功能,平均差2.31(95%CI 1.41;3.22)分,p<0.0001;总睾酮<8 nmol/l者改善幅度大于<12 nmol/l者。作者认为睾酮治疗可显著改善性腺功能减退男性的勃起功能及其他性功能参数。

要点

  • 睾酮治疗较安慰剂显著改善IIEF勃起功能域评分,平均差2.31(95%CI 1.41;3.22),p<0.0001。
  • 总睾酮<8 nmol/l者IIEF-EFD改善2.95(95%CI 1.86;4.03),大于<12 nmol/l者的1.47(95%CI 0.90;2.03),Q=5.61,p=0.02。
  • 合并糖尿病、肥胖等代谢紊乱时,睾酮治疗对勃起功能的改善幅度较低。

核心结论

  • 睾酮治疗可显著改善性腺功能减退男性的勃起功能及IIEF评估的其他性功能参数。
  • 作者认为性功能障碍应被视为睾酮缺乏的标志性表现,因为 normalization of serum T 可显著改善这些症状。
  • 作者建议,对于勃起功能障碍程度较轻的性腺功能减退男性,单用睾酮治疗可考虑为合理治疗;而勃起功能障碍较重者加用磷酸二酯酶5抑制剂等其他治疗可能更合适。

研究设计与样本

  • 研究类型为Meta分析,检索Medline、Embase和Cochrane数据库,纳入所有比较睾酮治疗对性功能影响的安慰剂对照随机临床试验。
  • 共检索到137篇文章,最终纳入14项研究,共2298名参与者,平均随访40.1周,平均年龄60.2±6.5岁。

主要发现

  • 以IIEF勃起功能域(IIEF-EFD)为结局,睾酮治疗较安慰剂显著改善勃起功能,平均差=2.31(95%CI 1.41;3.22)IIEF-EFD评分,p<0.0001。
  • 总睾酮<12 nmol/l者IIEF-EFD评分变化为1.47(95%CI 0.90;2.03),总睾酮<8 nmol/l者为2.95(95%CI 1.86;4.03),组间比较Q=5.61,p=0.02。
  • 合并糖尿病和肥胖等代谢紊乱时,睾酮治疗对勃起功能的效应幅度较低。
  • IIEF其他子域评估的性功能方面(包括性欲、性交满意度、性高潮和总体性满意度)也随睾酮治疗改善。

关键数值与推荐

  • 睾酮治疗较安慰剂改善IIEF-EFD评分的平均差为2.31(95%CI 1.41;3.22),p<0.0001。
  • 总睾酮<12 nmol/l者IIEF-EFD评分变化为1.47(95%CI 0.90;2.03),总睾酮<8 nmol/l者为2.95(95%CI 1.86;4.03),Q=5.61,p=0.02。

临床怎么用

  • 作者认为,对于勃起功能障碍程度较轻的性腺功能减退男性,单用睾酮治疗可考虑为合理治疗。
  • 作者认为,对于勃起功能障碍较重的男性,加用磷酸二酯酶5抑制剂等其他治疗可能更合适。
  • 作者提出性功能障碍应被视为睾酮缺乏的标志性表现,因为 normalization of serum T 可显著改善这些症状。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The interpretation of available clinical evidence related to the effect of testosterone (T) treatment (TTh) on sexual function has been inconsistent, in part due to the use of different and self-reported measures to assess outcomes. The International Index of Erectile Function (IIEF) is the most frequently used validated tool to assess male sexual function. OBJECTIVE: To perform a meta-analysis of available data evaluating the effect of TTh on male sexual function using IIEF as the primary outcome. EVIDENCE ACQUISITION: An extensive Medline, Embase, and Cochrane search was performed including all placebo-controlled randomized clinical trials enrolling men comparing the effect of TTh on sexual function. EVIDENCE SYNTHESIS: Out of 137 retrieved articles, 14 were included in the study enrolling 2298 participants, with a mean follow-up of 40.1 wk and mean age of 60.2±6.5 yr. Using IIEF-erectile function domain (IIEF-EFD) as the outcome, we found that TTh significantly improved erectile function compared with placebo (mean difference=2.31 [1.41;3.22] IIEF-EFD score, p<0.0001). Patients with more severe hypogonadism (total T<8 nmol/l) reported greater changes in final IIEF-EFD score when compared with those with a milder T deficiency (total T<12 nmol/l; 1.47 [0.90;2.03] and 2.95 [1.86;4.03] for total T<12 nmol/l and <8 nmol/l, respectively, Q=5.61, p=0.02). The magnitude of the effect was lower in the presence of metabolic derangements, such as diabetes and obesity. Other aspects of sexual function, as evaluated by IIEF subdomains, were also improved with TTh including libido, intercourse satisfaction, orgasm, and overall sexual satisfaction. CONCLUSIONS: TTh significantly improves erectile function and other sexual parameters as measured by IIEF in hypogonadal men. These results argue that sexual dysfunction should be considered a hallmark manifestation of T deficiency, since those symptoms can be significantly improved with normalization of serum T. In addition, these results suggest that TTh alone may be considered a reasonable treatment for hypogonadal men with milder degrees of erectile dysfunction, whereas the addition of other treatments, such as phosphodiesterase type 5 inhibitors, may be more appropriate for men with more severe erectile dysfunction. PATIENT SUMMARY: We investigated the effect of testosterone treatment on sexual function by performing a meta-analysis of all available studies that used the most frequently used assessment tool, the International Index of Erectile Function. We found that testosterone treatment significantly improves erectile dysfunction, as well as other aspects of sexual function, in men with testosterone deficiency. This treatment may be all that is required for hypogonadal men with milder erectile dysfunction; however, additional treatments may be necessary in more severe cases.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Corona G, Rastrelli G, Morgentaler A, et al. Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores. Eur Urol. 2017. PMID: 28434676. doi:10.1016/j.eururo.2017.03.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。